ライフサイエンスコーパス: metastasectomy

1 tify subpopulations who benefit from adrenal metastasectomy.

2 n those treated with either incomplete or no metastasectomy.

3 re in CR postoperatively, with 17% requiring metastasectomy.

4 HAI and systemic therapy was initiated after metastasectomy.

5 actors for survival in patients treated with metastasectomy.

6 astatic renal cell carcinoma with or without metastasectomy.

7 of successful chemotherapies have encouraged metastasectomy.

8 ve 13 and 62 months, respectively, following metastasectomy.

9 surgical resection, only half undergo liver metastasectomy.

10 metachronous pulmonary or synchronous liver metastasectomy.

11 placebo in patients with mRCC with NED after metastasectomy.

12 FS) in patients with mRCC rendered NED after metastasectomy.

13 nts with pulmonary recurrence underwent lung metastasectomy; 3-year freedom from recurrence was 37%.

14 y was associated with lower receipt of liver metastasectomy among US patients with CRLM.

15 We review the current role of metastasectomy and factors associated with outcome.

16 Patients, disease-free after CRC metastasectomy and perioperative chemotherapy (n = 74),

17 l is observed in patients undergoing adrenal metastasectomy and should be considered for subjects wit

18 went elective colon resection at the time of metastasectomy, and eight patients (3%) underwent this r

19 arcinoma, colorectal cancer, including liver metastasectomy, and esophageal carcinoma treated primari

20 concurrent imaging recurrence had subsequent metastasectomy, and only 3 were disease-free at the cuto

21 omes in larger series of patients undergoing metastasectomy as well as the indications for the proced

22 Ten patients underwent pulmonary resection/metastasectomy at various time points, the benefit of wh

23 use of other treatment modalities, including metastasectomy, chemotherapy, and radiation, was evaluat

24 The strongest evidence in favour of metastasectomy exists for colorectal cancer, in which re

25 (mean county-level rates were 0.24 for liver metastasectomy for CRLM and 0.75 for surgery for stage I

26 e the county-level odds of receiving a liver metastasectomy for CRLM associated with a 10% increase i

27 explain variability in the receipt of liver metastasectomy for CRLM.

28 imary outcome was county-level odds of liver metastasectomy for CRLM.

29 ents with no evidence of disease (NED) after metastasectomy for renal cell carcinoma are at high risk

30 gest that participants treated with complete metastasectomy for stage IV metastases have enhanced ove

31 Patients who underwent adrenal metastasectomy from 1994 to 2015 were identified from a

32 ly and patients in CR after chemotherapy and metastasectomy had a better outcome than patients with m

33 However, metastasectomy has been described for almost every organ

34 suggest that patients treated with complete metastasectomy have better survival and symptom control

35 Alternatively, treatment with metastasectomy (HR, 0.59; 95% CI, 0.46-0.74; P < .001) a

36 The survival benefit offered by pulmonary metastasectomies in patients with metastatic osteosarcom

37 Recent results from the "Pulmonary Metastasectomy in Colorectal Cancer" trial demonstrate n

38 IMIC (Minimally Invasive, Indocyanine-Guided Metastasectomy in Patients With Colorectal Liver Metasta

39 the (societal) cost-effectiveness of hepatic metastasectomy in patients with metachronous CRC liver m

40 Hepatic metastasectomy is a cost-effective option for selected p

41 Less often, pancreatic metastasectomy is done by enucleation or a pancreas spar

42 Pancreatic metastasectomy is most often done through a formal pancr

43 A reference strategy in which metastasectomy is not offered and imaging is not perform

44 upport to the idea that if complete surgical metastasectomy is technically feasible, then surgery sho

45 tions compared with standard follow-up after metastasectomy is warranted.

46 benefit of anatomical resection (AR) in lung metastasectomy (LM) of colorectal cancer (CRC) harboring

47 When considering metastasectomy, more aggressive approaches are generally

48 atrial septal defect closure (23%), cardiac metastasectomies or biopsy (4%), and simultaneous corona

49 Local treatment of metastases such as metastasectomy or radiotherapy remains controversial in

50 Analysis including metastasectomy patients made no difference in DFS or ove

51 Metastasectomy patients were to be analyzed separately b

52 After complete metastasectomy, patients were prospectively enrolled in

53 After nephrectomy with or without metastasectomy, patients were randomly assigned (1:1) to

54 Most literature on metastasectomy pertains to the resection of disease invo

55 Interventions included metastasectomy, radiotherapy modalities, and no local tr

56 rary group of patients who had undergone CRC metastasectomy, received similar perioperative therapy,

57 In selected patients undergoing adrenal metastasectomy, there were no significant differences in

58 It is currently unclear how rates of liver metastasectomy vary geographically in the US.

59 l from primary colon cancer surgery to liver metastasectomy was 12 months.

60 ry complete remission (CR) was not obtained, metastasectomy was considered.

61 The adjusted odds of undergoing a liver metastasectomy was lower in counties with higher poverty

62 Metastasectomy was rare; only 3.9% of patients underwent

63 Metastasectomies were done to procure tumour tissue to g

64 Patients with NED after metastasectomy were randomly assigned 1:1 to receive paz

65 High MTV and TGV in patients before metastasectomy were significantly associated with poorer

66 erapy in selected patients following hepatic metastasectomy where this aggressive approach might have

67 Metastasectomy with curative intent has become standard